Proactive Investors - Run By Investors For Investors

ANGLE acquires remaining stake in US subsidiary from Parsortix inventor

Having complete ownership of the US subsidiary is particularly important, said Angle, as it owns core intellectual property related to Parsortix
parsortix
ANGLE has bought out Hvichia by issuing him with £467,500 worth of shares

ANGLE plc (LON:AGL) now owns 100% of its North American subsidiary after buying out Georgi Hvichia’s 9.47% stake.

Hvichia is the original inventor of ANGLE’s Parsortix cancer detection technology. As such, he still holds a stake in ANGLE North America (ANAI) but the company has issued £467,500 worth of shares to acquire it.

READ: ANGLE finds new angle for cancer detection device

It means that Hvichia, who is currently a director of ANAI but will move to a scientific advisory board member role, now owns 1.08mln ANGLE shares, around 0.76% of the total share capital.

The AIM-quoted firm said the agreement gives it a clean 100% ownership of all its group companies, adding that the US subsidiary is particularly important as it owns core intellectual property related to Parsortix.

“We are pleased to reach an agreement with Georgi Hvichia, the original inventor of the Parsortix microfluidic technology, to acquire his remaining shareholding in our US operating subsidiary in exchange for ANGLE plc shares,” said chief executive Andrew Newland.

Angle shares were untraded at 96.2p in early deals on Monday.

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

Cancer cells
February 12 2019
The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise
1550762209_shutterstock_291998651.jpg
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use